<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab8">
 <label>Table 28.8</label>
 <caption>
  <p>Therapeutic agents and their effect (drug efficacy) on various genotype/strain of hepatitis</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Therapeutic agents</th>
    <th>Researchers/references</th>
    <th>Genotypes and disease</th>
    <th>Association and results</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>IFN</td>
    <td>Kao et al. (
     <xref ref-type="bibr" rid="CR80">2002</xref>, 
     <xref ref-type="bibr" rid="CR79">2000</xref>)
    </td>
    <td>C and D of HBV vs. B and A of HBV</td>
    <td>Liver diseases severity increases in C and D</td>
   </tr>
   <tr>
    <td>IFN and ribavirin</td>
    <td>Farci and Purcell (
     <xref ref-type="bibr" rid="CR44">2000</xref>)
    </td>
    <td>Genotype 1 and genotype 2 of HCV</td>
    <td>Poorer response (40 vs. 80 %)</td>
   </tr>
   <tr>
    <td>IFN</td>
    <td>King et al. (
     <xref ref-type="bibr" rid="CR84">2002</xref>)
    </td>
    <td>A/G heterozygous eIf-2α of HBV</td>
    <td>Significant (OR = 12.28; 95 % CI, 1.5–107.8; 
     <italic>p</italic> = 0.009)
    </td>
   </tr>
   <tr>
    <td>peg-IFN-alpha and RBV</td>
    <td>Suppiah et al. (
     <xref ref-type="bibr" rid="CR165">2009</xref>)
    </td>
    <td>IL-28B with HCV</td>
    <td>Significant (
     <italic>p</italic> = 7.06 × 10
     <sup>–8</sup>; OR = 3.36; 95 % CI, 2.15–5.35)
    </td>
   </tr>
   <tr>
    <td rowspan="2">peg-IFN-alpha and RBV</td>
    <td rowspan="2">Tanaka et al. (
     <xref ref-type="bibr" rid="CR166">2009</xref>)
    </td>
    <td rowspan="2">Genotype 1 of HCV two SNPs (rs8099917) and (rs12980275) of IL-28B</td>
    <td>Strong association with null virologic response (NVR)</td>
   </tr>
   <tr>
    <td>(
     <italic>p</italic> = 3.11 × 10
     <sup>–15</sup>) and (
     <italic>p</italic> = 1.93 × 10
     <sup>–13</sup>)
    </td>
   </tr>
   <tr>
    <td>peg-IFN-alpha and RBV</td>
    <td>Rauch et al. (
     <xref ref-type="bibr" rid="CR143">2010</xref>)
    </td>
    <td>(rs8099917)T/G SNP with HCV genotype 1:G allele fail to respond of IL-28B</td>
    <td>Null virologic response (NVR) (OR = 2.31; 95 % CI, 1.74–3.06; 
     <italic>p</italic> = 6.07 × 10
     <sup>–9</sup>) vs. sustained vs. sustained viral response (SVR) (OR = 5.19; 95 % CI, 2.90–9.30; 
     <italic>p</italic> = 3.11 × 10
     <sup>–8</sup>)
    </td>
   </tr>
  </tbody>
 </table>
</table-wrap>
